Kyverna Therapeutics, Inc.
KYTX
$7.18
$0.629.45%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 12.58% | 5.72% | -19.06% | -8.69% | -19.75% |
| Total Depreciation and Amortization | -19.42% | 2.79% | -11.01% | 0.90% | 5.28% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 36.98% | -0.93% | 930.18% | -114.18% | 484.52% |
| Change in Net Operating Assets | -207.61% | 476.69% | -6,523.53% | -99.35% | 19.17% |
| Cash from Operations | -35.59% | 28.87% | -21.19% | -34.82% | -13.71% |
| Capital Expenditure | 50.00% | -- | -- | -421.57% | 90.08% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -22.91% | 422.97% | -81.25% | 3,724.42% | 101.16% |
| Cash from Investing | -22.66% | 422.89% | -80.91% | 4,222.78% | 101.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 54.20% | 23.17% | -38.06% | -2.07% | -2.54% |
| Issuance of Common Stock | -- | -100.00% | -90.63% | -64.44% | 23.29% |
| Repurchase of Common Stock | 15.69% | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -342.11% | -- | -- | 100.00% |
| Cash from Financing | 329.28% | -56.76% | -92.56% | -41.45% | 73.29% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -461.82% | 91.37% | -393.56% | 70.13% | 70.90% |